ANI Pharmaceuticals Inc. (ANIP)
ANI Pharmaceuticals Inc. (ANIP) Stock Price, Analysis & Data
| Bid | 56.91 |
| Market Cap | 1.74B |
| Revenue (ttm) | 978.38M |
| Net Income (ttm) | 99.6M |
| Beta | 0.46 |
| EPS (ttm) | 4.59 |
| PE Ratio (ttm) | 16.47 |
| Forward PE | 7.18 |
| P/B (ttm) | 2.71 |
| P/S (ttm) | 1.78 |
| Earnings Date | Nov 6, 2026 |
| Ask | 103.53 |
| Volume | 56,465 |
| Avg. Volume (20D) | 338,788 |
| Open | 74.47 |
| Previous Close | 74.77 |
| Day's Range | 73.39 - 75.67 |
| 52-Week Range | 70.15 - 99.50 |
| Analyst | Buy |
| Price Target | 109.5 (44.82%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ANIP
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to nat...
Full Company ProfileFinancial Performance
In 2025, ANI Pharmaceuticals's revenue was 883.37M, an increase of 43.78% compared to the previous year's 614.38M. Earnings were 78.34M, a decrease of -522.94%.
Financial StatementsAnalyst Forecast
According to 8 analyst ratings, the average rating for ANIP stock is "Buy". The 12-month stock price forecast is 109.5, which is upside of 44.82% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
